معرفی
Muhammed Rahaman is a Research Fellow at the University of South Australia (UniSA) within the Clinical & Health Sciences school. He specializes in cancer therapeutics, focusing on cyclin-dependent kinase (CDK) inhibitors and their applications in oncology. His work spans drug design, pre-clinical development, and targeted therapies for cancers such as breast, prostate, and leukaemia. Key areas of research include CDK4/6, CDK8, CDK9, and Aurora kinase inhibition, with an emphasis on improving chemotherapy outcomes and identifying novel therapeutic targets.
His research interests explore mechanisms of cancer cell proliferation, apoptosis induction, and drug resistance. He has contributed to the development of orally bioavailable CDK inhibitors like AU2-94, LS007, and CDKI-73, demonstrating efficacy in pre-clinical models. His studies highlight dual kinase inhibition strategies and repurposing existing drugs (e.g., rilpivirine) for anti-leukaemic activity.
Rahaman’s publications reflect a strong focus on translational oncology, with recent work advancing CDK9 inhibitors for colorectal and triple-negative breast cancer. His research integrates molecular pharmacology, structural biology, and clinical oncology to bridge laboratory discoveries and clinical applications. He currently supervises research degree candidates.
